Treatment outcomes of HIV-positive patients on first-line antiretroviral therapy in private versus public HIV clinics in Johannesburg, South Africa

被引:16
作者
Moyo, Faith [1 ]
Chasela, Charles [2 ,3 ]
Brennan, Alana T. [1 ,4 ]
Ebrahim, Osman [5 ]
Sanne, Ian M. [1 ,6 ]
Long, Lawrence [1 ]
Evans, Denise [1 ]
机构
[1] Univ Witwatersrand, Hlth Econ & Epidemiol Res Off, Dept Internal Med, Sch Clin Med,Fac Hlth Sci, Unit 2,39 Empire Rd, ZA-2193 Johannesburg, South Africa
[2] Univ Witwatersrand, Sch Publ Hlth, Epidemiol & Biostat Dept, Fac Hlth Sci, Johannesburg, South Africa
[3] Human Sci Res Council, Epidemiol & Strateg Informat ESI HIV AIDS STIs &, Pretoria, South Africa
[4] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA
[5] Brenthurst Clin, Parktown, South Africa
[6] Right To Care, Helen Joseph Hosp, Johannesburg, South Africa
来源
CLINICAL EPIDEMIOLOGY | 2016年 / 8卷
关键词
health systems; attrition; HIV programs; viral suppression; SUB-SAHARAN AFRICA; EARLY MORTALITY; FOLLOW-UP; CARE; PROGRAM; ADHERENCE; SECTOR; COHORT; INDIA; RISK;
D O I
10.2147/CLEP.S93014
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Despite the widely documented success of antiretroviral therapy(ART), stakeholders continue to face the challenges of poor HIV treatment outcomes. While many studies have investigated patient-level causes of poor treatment outcomes, data on the effect of health systems on ART outcomes are scarce. Objective: We compare treatment outcomes among patients receiving HIV care and treatment at a public and private HIV clinic in Johannesburg, South Africa. Patients and methods: This was a retrospective cohort analysis of ART naive adults (>= 18.0 years), initiating ART at a public or private clinic in Johannesburg between July 01, 2007 and December 31, 2012. Cox proportional-hazards regression was used to identify baseline predictors of mortality and loss to follow-up (>3 months late for the last scheduled visit). Generalized estimating equations were used to determine predictors of failure to suppress viral load (>= 400 copies/mL) while the Wilcoxon rank-sum test was used to compare the median absolute change in CD4 count from baseline to 12 months post-ART initiation. Results: 12,865 patients initiated ART at the public clinic compared to 610 at the private clinic. The patients were similar in terms of sex and age at initiation. Compared to public clinic patients, private clinic patients initiated ART at higher median CD4 counts(159 vs 113 cells/mm(3)) and World Health Organization stage I/II(76.1% vs 58.5%). Adjusted hazard models showed that compared to public clinic patients, private clinic patients were less likely to die(adjusted hazard ratio [aHR] 0.50; 95% confidence interval [CI] 0.35-0.70) but were at increased risk of loss to follow-up(aHR 1.80; 95% CI 1.59-2.03). By 12 months post-ART initiation, private clinic patients were less likely to have a detectable viral load(adjusted relative risk 0.65; 95% CI 0.49-0.88) and recorded higher median CD4 change from baseline(184 cells/mm(3) interquartile range 101-300 vs 158 cells/mm3 interquartile range 91-244), when compared to public clinic patients. Conclusion: We identified differences in treatment outcomes between the two HIV clinics. Findings suggest that the type of clinic at which ART patients initiate and receive treatment can have an impact on treatment outcomes. Further research is necessary to provide more conclusive results.
引用
收藏
页码:37 / 46
页数:10
相关论文
共 50 条
  • [41] Clinical and immunological failure among HIV-positive adults taking first-line antiretroviral therapy in Dire Dawa, eastern Ethiopia
    Lenjiso, Getinet Abera
    Endale, Berhanu Seyoum
    Bacha, Yadeta Dessie
    BMC PUBLIC HEALTH, 2019, 19 (1)
  • [42] Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa
    Brennan, Alana T.
    Jamieson, Lise
    Crowther, Nigel J.
    Fox, Matthew P.
    George, Jaya A.
    Berry, Kaitlyn M.
    Stokes, Andrew
    Maskew, Mhairi
    Sanne, Ian
    Long, Lawrence
    Cassim, Naseem
    Rosen, Sydney
    PLOS ONE, 2018, 13 (10):
  • [43] Impact of the test and treat policy on delays in antiretroviral therapy initiation among adult HIV positive patients from six clinics in Johannesburg, South Africa: results from a prospective cohort study
    Onoya, Dorina
    Sineke, Tembeka
    Hendrickson, Cheryl
    Mokhele, Idah
    Maskew, Mhairi
    Long, Lawrence C.
    Fox, Matthew
    BMJ OPEN, 2020, 10 (03):
  • [44] Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa
    Evans, Denise
    Hirasen, Kamban
    Berhanu, Rebecca
    Malete, Given
    Ive, Prudence
    Spencer, David
    Badal-Faesen, Sharlaa
    Sanne, Ian M.
    Fox, Matthew P.
    AIDS RESEARCH AND THERAPY, 2018, 15
  • [45] Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice
    Tesson, Thomas
    Blot, Mathieu
    Fillion, Aurelie
    Djerad, Hama
    Cagnon-Chapalain, Josephine
    Creuwels, Aline
    Waldner, Anne
    Duong, Michel
    Buisson, Marielle
    Mahy, Sophie
    Chavanet, Pascal
    Piroth, Lionel
    ANTIVIRAL THERAPY, 2016, 21 (08) : 715 - 724
  • [46] Prevalence of metabolic syndrome in HIV-infected patients naive to antiretroviral therapy or receiving a first-line treatment
    Calza, Leonardo
    Colangeli, Vincenzo
    Magistrelli, Eleonora
    Rossi, Nicolo'
    Del Turco, Elena Rosselli
    Bussini, Linda
    Borderi, Marco
    Viale, Pierluigi
    HIV CLINICAL TRIALS, 2017, 18 (03): : 110 - 117
  • [47] Predictors of antiretroviral treatment failure to the first line therapy: a cross-sectional study among Iranian HIV-positive adults
    Hashempour, Ava
    Khodadad, Nastaran
    Ziaei, Reza
    Rezaei, Behzad
    Ghasabi, Farzaneh
    Falahi, Shahab
    Kenarkouhi, Azra
    Davarpanah, Mohammad Ali
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [48] Who Starts? Factors Associated with Starting Antiretroviral Therapy among Eligible Patients in Two, Public HIV Clinics in Lilongwe, Malawi
    Feldacker, Caryl
    Johnson, Derek
    Hosseinipour, Mina
    Phiri, Sam
    Tweya, Hannock
    PLOS ONE, 2012, 7 (11):
  • [49] Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First-Line Antiretroviral Therapy in South Africa
    Hoffmann, Christopher J.
    Charalambous, Salome
    Sim, John
    Ledwaba, Joanna
    Schwikkard, Graham
    Chaisson, Richard E.
    Fielding, Katherine L.
    Churchyard, Gavin J.
    Morris, Lynn
    Grant, Alison D.
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (12) : 1928 - 1935
  • [50] Antiretroviral treatment uptake and attrition among HIV-positive patients with tuberculosis in Kibera, Kenya
    Tayler-Smith, K.
    Zachariah, R.
    Manzi, M.
    Kizito, W.
    Vandenbulcke, A.
    Sitienei, J.
    Chakaya, J.
    Harries, A. D.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2011, 16 (11) : 1380 - 1383